2024年5月1日,葛兰素史克发布一季度财报,营业收入73.67亿英镑,同比增长10%,去除新冠产品影响,同比增长13%。 2024年Q1疫苗业务呼吸道RSV疫苗Arexvy增长22%,带状疱疹Shingrix创销售额纪录!疫苗业务已成为葛兰素史克业绩增长的核心驱动力,带疱疫苗销售...
16 Dec 2024 9 Jan 2025 Ordinary: 15pADR: $0.3768915 Q2 2024 31 Jul 2024 15 Aug 2024 16 Aug 2024 16 Aug 2024 19 Sep 2024 10 Oct 2024 Ordinary: 15pADR: $0.3928131 Q1 2024 1 May 2024 16 May 2024 16 May 2024 17 May 2024 20 Jun 2024 11 Jul 2024 Ordinary:...
GSK plc 2024 Q3 - Results - Earnings Call PresentationWed, Oct. 30, 2024 GSK plc (GSK) Q3 2024 Earnings Call TranscriptSA TranscriptsWed, Oct. 30, 2024 GSK plc (GSK) Q2 2024 Earnings Call TranscriptSA TranscriptsWed, Jul. 31, 2024 GSK plc (GSK) Q1 2024 Earnings Call TranscriptSA Tran...
Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK’s Q1 Results for 2022 and any impacts of the COVID-19 pandemic. References [1] Naymagon, L., & Mascarenhas, J. (2017). Myelofibrosis-Related Anemia: Current ...
据不完全统计,2024 Q1共发生28起CGT领域的合作,其中总潜在价值最高的为诺华和Voyager价值13亿美元的基于新型基因疗法的合作。1、Allogene与Arbor。3月12日,Allogene Therapeutics与Arbor Biotechnologies双方共同宣布了一项非独家的全球基因编辑许可协议,将Arbor专有的CRISPR基因编辑技术用于Allogene的下一代AlloCAR T™...
Aug. 1, 2024 at 10:02 a.m. ET by Barron's GSK’s better-than-expected results overshadowed by Zantac litigation Jul. 31, 2024 at 5:45 a.m. ET by Louis Goss Biotech and Pharma GSK Will Pay Up to $1.5 Billion for CureVac’s mRNA Vaccines Jul. 3, 2024 at 10:18 a.m. ...
2024-11-13Interim Payment 0.15 GBP 2024-08-14Interim Payment 0.15 GBP 2024-05-15Interim Payment 0.15 GBP Annual results Quarterly results Quarterly revenue - Rate of surprise Net sales - Rate of surprise Annual profits - Rate of surprise
the timing of and results of interactions with regulators; Zymeworks’ clinical development of its product candidates and enrollment in its clinical trials; the timing and status of ongoing and future studies and the related data; expectations regarding future regulatory filings and approvals and ...
, and we'll provide news on progress here alongside that of innovation and performance throughout the year. An investor update for the new consumer company is also expected in the first half of 2022. So I'll now hand over to Iain to take you through the detail of this year's results....
1a). Accordingly, the results of immunohistochemistry (IHC) and western blotting analysis showed that STK17B protein was upregulated in HCC tissues (Fig. 1b, c). Moreover, clinicopathological analysis revealed that STK17B expression level was positively associated with tumor size (P = 0.044...